Hossein Borghaei
Interim Chair, Department of Hematology/Oncology · Temple University Hospital
Credentials: · · · ·
History
PresentDepartment of Hematology/Oncology · Temple University Hospital
- Present
Division of Thoracic Medical Oncology · Temple University Hospital
- Present
Immune Monitoring Facility · Temple University Hospital
Research
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · First of 28 authors · 7,953 citations
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
New England Journal of Medicine · 2018 · 2,498 citations
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2019 · 2,292 citations
24 papers
23 papers
- LH
16 papers
14 papers
14 papers
- GO
13 papers
13 papers
13 papers
Grants
- 1997–2030
Comprehensive Cancer Center Program at Fox Chase
National Cancer Institute · P30
Project lead · $1.1M · Research Inst of Fox Chase Can Ctr
Clinical trials
- 2022–2024
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
Principal investigator · Withdrawn · Phase 2
Fox Chase Cancer Center
- 2020–2027
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Principal investigator · Active not recruiting · Phase 2
Fox Chase Cancer Center
- 2019–2027
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
- 2015–2016
Principal investigator · Terminated
Fox Chase Cancer Center